Published in Medical Letter on the CDC and FDA, May 20th, 2007
"We expect to begin Phase 3 testing with ozarelix in patients with BPH later this year, and the opportunity to conduct trials with ozarelix at select sites in both Canada and the U.S. will enable us to enroll and begin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.